Altimmune Announces First Quarter 2025 Financial Results and Business Update
Provided By GlobeNewswire
Last update: May 13, 2025
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025
Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively
Read more at globenewswire.comNASDAQ:ALT (6/3/2025, 10:06:57 AM)
5.39
+0.09 (+1.7%)
Find more stocks in the Stock Screener
